Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Industry sector: Medical
Sector classification: Biological products, except diagnostic
Deep Learning based analysis and prediction model for Gilead Sciences, Inc. (GILD) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.
Model is in the production pipeline since Oct. 23, 2015.
Market data for GILD model training are being downloaded from the Quandl premium datasets on a daily basis.
Model is being retrained on a regular basis.
|% Held by Insiders||1.30%|
|% Held by Institutions||78.43%|
|EPS (last reported FY)||$8.56|
|EPS (last reported Q)||$1.37|
|EPS, estimated (last reported Q)||$1.65|
|Total revenues||$26 B|
|Net income||$5 B|